BIO-TECHNE Corp financials

  1. Home
  2. Financials
  3. TECH
TECH CIK 0000842023

Source: EDGAR filings · Built 2026-06-02T04:09:49Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 256.55M 236.10M 216.15M 280.36M 307.86M 153.47M
EBITDA 212.16M 318.40M 406.18M 397.66M 325.04M 240.16M
Working Capital 432.45M 458.04M 492.97M 429.54M 358.32M 414.25M
Net Debt 281.87M 267.75M 274.39M 140.90M 208.96M 274.40M
Gross Margin 64.80% 66.41% 67.72% 68.42% 67.97% 65.41%
Operating Margin 8.38% 17.83% 26.30% 26.83% 25.49% 21.31%
Net Margin 6.02% 14.50% 25.10% 24.61% 15.08% 31.04%
Return on Equity (ROE) 3.83% 8.13% 14.51% 15.99% 8.98% 16.60%
Return on Assets (ROA) 2.87% 6.22% 10.81% 11.86% 6.20% 11.31%
Current Ratio 3.46× 3.87× 4.84× 3.44× 3.35× 4.88×
Debt-to-Equity 0.23× 0.20× 0.23× 0.18× 0.26× 0.30×
Effective Tax Rate 25.45% 9.47% 15.71% 12.70% 5.80% 17.07%
Cash Conversion Ratio 3.92× 1.78× 0.89× 1.20× 2.51× 0.90×
Accruals Ratio -0.08× -0.05× 0.01× -0.02× -0.09× 0.01×
SBC % of Revenue 3.35% 3.28% 3.45% 3.82% 5.26% 4.38%
CapEx Coverage 9.27× 4.75× 6.65× 7.24× 7.95× 3.97×
Free Cash Flow Per Share $1.61 $1.47 $1.34 $1.71 $1.90 $3.90

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 111.85× 68.24× 46.38× 52.20× 129.39× 45.37×
P/FCF 32.03× 48.79× 61.13× 50.73× 59.21× 67.79×
FCF Yield 3.12% 2.05% 1.64% 1.97% 1.69% 1.48%
EV / EBITDA 38.91× 36.44× 32.36× 136.90× 54.61× 43.42×
P/S 6.54× 9.78× 11.32× 49.11× 18.84× 13.75×
P/B 4.16× 5.48× 6.54× 31.91× 11.22× 7.35×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.22B 1.16B 1.14B 1.11B 931.03M 738.69M
Revenues 1.22B 1.16B 1.14B — — —
Cost of Goods and Services Sold 429.36M 389.33M 366.89M 349.10M 298.18M 255.50M
Gross Profit 790.27M 769.73M 769.82M 756.50M 632.85M 483.19M
Selling, General and Administrative Expense 588.52M 466.38M 378.38M 372.77M 324.95M 260.58M
Operating Expenses 688.02M 563.04M 470.87M 459.91M 395.55M 325.77M
Operating Income (Loss) 102.25M 206.69M 298.94M 296.59M 237.30M 157.42M
Income Tax Expense (Benefit) 25.06M 17.58M 53.22M 38.29M 8.59M 47.18M
Net Income (Loss) Attributable to Parent 73.40M 168.10M 285.26M 272.05M 140.41M 229.30M
Earnings Per Share, Basic $0.47 $1.07 $1.81 $1.73 $0.91 $6.00
Weighted Average Number of Shares Outstanding, Basic 157.52M 157.71M 157.18M 156.87M 154.99M 38.20M
Earnings Per Share, Diluted $0.46 $1.05 $1.76 $1.66 $0.87 $5.82
Weighted Average Number of Shares Outstanding, Diluted 159.72M 160.77M 161.85M 164.11M 161.93M 39.40M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 162.19M 151.79M 180.57M 172.57M 199.09M 146.63M
Assets, Current 608.30M 617.42M 621.48M 605.56M 510.61M 520.92M
Assets 2.56B 2.70B 2.64B 2.29B 2.26B 2.03B
Liabilities, Current 175.85M 159.38M 128.51M 176.02M 152.28M 106.67M
Stockholders' Equity Attributable to Parent 1.92B 2.07B 1.97B 1.70B 1.56B 1.38B
Common Stock, Shares, Outstanding 154.97M 158.22M 157.64M 156.64M 38.96M 38.45M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 287.56M 298.98M 254.39M 325.27M 352.16M 205.22M
Payments to Acquire Property, Plant, and Equipment 31.01M 62.88M 38.24M 44.91M 44.30M 51.74M
Net Cash Provided by (Used in) Investing Activities -35.18M -203.03M -265.65M -96.85M -243.52M 27.09M
Payments for Repurchase of Common Stock 275.73M 80.04M 19.56M 160.95M 43.18M 50.11M
Net Cash Provided by (Used in) Financing Activities -253.91M -122.40M 22.62M -242.85M -62.55M -183.80M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TECH CIK 0000842023), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

LOAN

MANHATTAN BRIDGE CAPITAL, INC.

TBPH

THERAVANCE BIOPHARMA, INC.

CLVT

CLARIVATE PLC